Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Nomura’s Saion Mukherjee picks Dr Reddy’s as top pharma bet amid semaglutide opportunity
Saion Mukherjee, Managing Director & Head of Equity Research at Nomura says Indian pharmaceutical companies are preparing to tap the opportunity as semaglutide goes off patent. While several large firms such as Sun Pharma, Lupin and Zydus could benefit from the growing diabetes and obesity drug market, Mukherjee highlighted Dr Reddy’s as his top pick in the sector. He said the opportunity will play out across domestic and global markets, with semaglutide likely to become an important growth driver for Indian pharma companies in the coming years.
Lupin slips as Ankleshwar facility gets two observations from USFDA
Lupin declined 1.84% to Rs 2,301.25 after the US Food and Drug Administration (US FDA) concluded an inspection of its manufacturing facility in Ankleshwar, India, issuing a Form 483 with two observations.
Lupin receives form 483 with 2 observations after US FDA inspection at Ankleshwar facility
On Friday (March 6), shares of Lupin Ltd ended at ₹2,335.55, up by ₹3.15, or 0.14%, on the BSE.
Lupin shares hit 52-week high after registering gains for six consecutive months
Lupin is on track to hit $1 billion in US sales this fiscal year. Its US revenue guidance is above $1 billion for the financial year 2027. Its margins are estimated to be between 26% - 27% for the current year and 25% for the next year as research and development (R&D) expenses rise.
Lupin among 7 stocks that hit 52-week high; rally up to 25% in a month
Lupin gets Establishment Inspection Report from the USFDA for its Goa facility
The US drug regulator had inspected Lupin's Goa facility, a key unit for the company, between November 10 and November 21, 2025.
Stocks to Watch for February 26: IRFC, Tata Capital, Lupin, KFin Tech and more
Tata Capital Ltd, IRFC, Lupin, KFin Technologies, Emmvee Photovoltaic Power, and Shaily Engineering Plastics announce key financial and operational updates. Here are few stocks to track ahead of Thursday's trading session.
Lupin says GST inspection at Maharashtra office underway; business, finances unaffected, shares rise
In a regulatory exchange, the company said it is cooperating with authorities and that the proceedings have no impact on its financials, operations or other activities.
Lupin gets US FDA nod for Brivaracetam oral solution, launches in US market
Shares of Lupin Ltd ended at ₹2,248.90, up by ₹3.80, or 0.17%, on the BSE.
Pharma outlook: Kotak Institutional prefers contract manufacturing, hospitals
Alankar Garude, Analyst at Kotak Institutional Equities, said US generics should be assessed through a bottom-up lens, where company-specific fundamentals matter more than broad sector trends. Within the segment, Kotak prefers firms with meaningful US exposure, including Lupin.
Trade Spotlight: How should you trade GAIL, Action Construction Equipment, Niva Bupa Health, ITC Hotels, Lupin, Vardhman Textiles, and others on June 19?
The market may give up some gains due to profit booking after the five-day rally. However, the overall trend remains positive. Below are some short-term trading ideas to consider.
Stocks to Watch Today: InterGlobe Aviation, Concord Biotech, NMDC, Lumax Auto Tech, Olectra Greentech, Cyient. Lupin, PB Fintech in focus on 01 June
Stocks to Watch, 1 Jun: InterGlobe Aviation, Gujarat Gas, Concord Biotech, Indian Renewable Energy Development Agency, NMDC, Glenmark Pharma, Olectra Greentech, Lumax Auto Technologies, Inox Wind, PNC Infratech, and Cyient will be in focus on June 1.